Journal of Clinical & Experimental Pharmacology

Global status of biosimilars and prospects in Asia

Co-organized Event International Conference on Toxicology and Clinical Pharmacology & 2^nd International Conference on Generic Drugs and Biosimilars

December 14-16, 2017 Rome, Italy

Md Abu Zafor Sadek

Institute of Business Administration, University of Dhaka, Bangladesh

Posters & Accepted Abstracts: Clin Exp Pharmacol

Abstract:

Almost one decade back the first biosimilar was launched in Europe. Now they have 15 biosimilars and all are well accepted since high price branded biologics were tough to reach by many patients. Recently biosimilars has been endorsed everywhere in the world starting from underdeveloped to developed countries. United States Food and Drug Administration (USFDA) approved the first biosimilar in 2015 and currently they have three biosimilars which are playing pivotal role in price cutting of branded biologics. They also have many biosimilars to be launched shortly. Australia, Canada, Africa and Asia are also aggressive with biosimilars; especially India, Korea and China made remarkable efforts in biosimilars. However, considering the changes in disease pattern, increasing use of biological drugs, huge number of population, rising health awareness, recent economic growth, success history of some biologic companies, dependence on generic items, price sensitivity, relax regulation, growing health budget, very low production cost and other relevant factors Asia is an important hub for biosimilars. Therefore, this study found out the prospects of biosimilars in Asia.